Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Calluna secures FDA orphan drug designation for CAL101 in IPF
CAL101 is intended for the treatment of idiopathic pulmonary fibrosis (IPF). It is currently studied in the Phase II AURORA trial, with patient recruitment underway in the US,
CAL101 is intended for the treatment of idiopathic pulmonary fibrosis (IPF). It is currently studied in the Phase II AURORA trial, with patient recruitment underway in the US,
Tremfya is a fully-human, dual-acting monoclonal antibody that works by selectively targeting IL-23, a protein involved in abnormal immune activity. The drug is already approved in the US
ThecaFlex DRx is an investigational implantable device to deliver antisense oligonucleotides (ASOs) intrathecally. The device administers medicines to patients with neurologic disorders. It is designed to offer an
This authorisation is specifically for patients who have symptomatic TGCT, with significant physical functional decline, and for whom surgical intervention is either not an option or would lead
The investment round was jointly spearheaded by Qiming Venture Partners USA and Versant Ventures. It also saw contributions from SV Health Investors, the company’s founding investor, and new
The funds will help YolTech in advancing its clinical programmes and global strategic execution. Established in 2021, YolTech Therapeutics is stated to be advancing next-generation in vivo gene-editing
Turbine noted that laboratory models often fail to capture the molecular diversity and biological complexity of many solid tumours found in patients. This limitation hampers the development of
Osteoarthritis is a degenerative condition impacting more than 30 million adults in the US. This collaboration will focus on the promotion of Zilretta (triamcinolone acetonide extended-release injectable suspension),
The company completed a positive Phase IIa trial of the candidate for chronic subjects with peripheral neuropathic pain. It is now preparing for further clinical development and has
The new facility is claimed to enhance Biosynth’s ability to manufacture GMP bioconjugates, supporting the production of intermediates and active pharmaceutical ingredients from early clinical stages till late-phase